Litigation Details for KPH Healthcare Services, Inc. v. Mylan N.V. (D. Kan. 2020)
✉ Email this page to a colleague
KPH Healthcare Services, Inc. v. Mylan N.V. (D. Kan. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-02-14 |
| Court | District Court, D. Kansas | Date Terminated | |
| Cause | 15:2 Antitrust Litigation | Assigned To | Daniel Dale Crabtree |
| Jury Demand | Plaintiff | Referred To | Teresa James |
| Patents | 7,132,570; 7,449,012; 7,794,432; RE37,516 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in KPH Healthcare Services, Inc. v. Mylan N.V.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for KPH Healthcare Services, Inc. v. Mylan N.V. (D. Kan. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-02-14 | 1 | Complaint (attorney) | 8, 2009), alleging infringement of U.S. Patent No. 7,449,012. King filed a First Amended Complaint on…faith, during patent prosecution. A patent applicant is required to disclose to the Patent and Trademark… applicant for patent infringement. If the brand name manufacturer initiates a patent infringement action…does not actually infringe the listed patent(s) and/or the patent is invalid and unenforceable. As a result…co-Defendants hold four patents on the EpiPen. However, Defendants do not hold a patent on the drug delivered | External link to document |
| 2021-09-21 | 128 | Amended Complaint | , alleging infringement of U.S. Patent No. 7,449,012 (the “‘012 Patent”). Mylan 39 …. “Process patents, patents claiming packaging, patents claiming metabolites, and patents claiming intermediates…ingredient) patents, drug product (formulation and composition) patents, and method-of- use patents.” 21 C.F.R…faith, during patent prosecution. A patents applicant is required to disclose to the Patent and Trademark…authorization prior to the expiration of the listed patent(s). Patents issued after NDA approval must be listed | External link to document |
| 2022-08-23 | 252 | Order on Motion to Compel | Document 252 Filed 08/23/22 Page 11 of 17 “7,132,570 B2,” and “RE37, 516 E”) which Plaintiffs want …self-evident because (1) the patents and patent numbers relate to the patents at issue in the Teva litigation…interest doctrine” as it relates to the Teva patent and other patent litigations. Mylan disagrees, asserting…of four search terms (“Armodafinil”, “570 Patent,” “516 Patent,” 21 ECF No. 158 at 3. …law when deciding issues unique to patent law, but on non-patent issues a court applies the law of the | External link to document |
| 2020-09-10 | 54 | Amended Complaint | D. Del.), alleging infringement of U.S. Patent No. 7,449,012. King filed a First Amended Complaint on…faith, during patent prosecution. A patent applicant is required to disclose to the Patent and Trademark… applicant for patent infringement. If the brand name manufacturer initiates a patent infringement action…does not actually infringe the listed patent and/or the patent is invalid and unenforceable. As a result…co-Defendants hold four patents on the EpiPen. However, Defendants do not hold a patent on the drug delivered | External link to document |
| 2020-11-03 | 72 | Amended Complaint | D. Del.), alleging infringement of U.S. Patent No. 7,449,012. King filed a First Amended Complaint on…. “Process patents, patents claiming packaging, patents claiming metabolites, and patents claiming intermediates…ingredient) patents, drug product (formulation and composition) patents, and method-of- use patents.” 21 C.F.R…faith, during patent prosecution. A patent applicant is required to disclose to the Patent and Trademark…that a particular patent is eligible for Orange Book listing. 34. A patent applicant is subject | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
